<DOC>
	<DOCNO>NCT03028467</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , 3 dosage level , placebo-controlled , Phase 1/2 study design evaluate pharmacokinetics , safety , tolerability , efficacy monoclonal antibody GSK3196165 , Japanese subject active moderate-severe rheumatoid arthritis ( RA ) despite treatment methotrexate ( MTX ) . The subject receive GSK3196165 combination methotrexate therapy 12 week treatment period . Approximately 55 subject screen achieve 40 randomized subject , approximately 10 subject treatment group .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Safety GSK3196165 Combination With Methotrexate Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Age : &gt; =20 year time signing informed consent Japanese rheumatoid arthritis ( RA ) subject meets American College Rheumatology European League Against Rheumatism ( ACR/EULAR ) 2010 RA Classification Criteria Functional class I , II III define 1992 ACR Classification Functional Status RA Disease duration &gt; =12 week ( time onset subjectreported symptom either pain stiffness swell hand , foot wrist ) . Swollen joint count &gt; =4 ( 66joint count ) tender joint count &gt; =4 ( 68joint count ) screen Day 1 DAS28 ( CRP ) &gt; =3.2 screen CReactive Protein ( CRP ) &gt; =0.5 milligram ( mg ) /deciliter ( dL ) screening Must previously receive methotrexate ( MTX ) ( 816 mg weekly ) orally least 12 week screen , stable tolerate dose &gt; =4 week prior Day 1 &gt; =40 kilogram ( kg ) Male female subject eligible participate long meet agree abide contraceptive criterion Written inform consent prior screen procedure include discontinuation prohibit medication Willing continue initiate treatment oral folic acid ( 5 mg/week ) treat entire study ( mandatory comedication MTX treatment ) Diffusing capacity lung carbon monoxide ( DLCO ) &gt; =60 % predict ; force expiratory volume 1 second ( FEV1 ) &gt; =70 % predict ; force vital capacity ( FVC ) &gt; =80 % predict For subject DLCO value ≥60 % &lt; 70 % , baseline chest highresolution compute tomography ( HRCT ) must perform screening period , recommend subject review local pulmonologist exclude significant preexist respiratory disease . No evidence active latent infection Mycobacterium tuberculosis ( TB ) , define follow : No history active latent TB infection irrespective treatment status A negative Tspot test within 4 week baseline ( Day 1 ) Chest Xray within 12 week Day 1 , locally read radiologist , evidence current previous pulmonary tuberculosis Pregnant lactate woman History inflammatory rheumatologic autoimmune disorder , Sjögren 's syndrome secondary RA History respiratory disease ( opinion investigator ) would compromise subject safety ability subject complete study ( e.g . significant interstitial lung disease , pulmonary fibrosis , chronic obstructive pulmonary disease ( COPD ) , moderatesevere asthma , bronchiectasis , previous pulmonary alveolar proteinosis ( PAP ) Clinicallysignificant unstable ( opinion investigator ) persistent cough dyspnea unexplained QT interval correct heart rate ( QTc ) &gt; 450 millisecond ( msec ) QTc &gt; 480 msec subject bundle branch block . The QTc QT interval correct heart rate accord Fridericia 's formula ( QTcF ) Liver function test : alanine aminotransferase ( ALT ) &gt; =1.5x upper limit normal ( ULN ) ; aspartate transaminase ( AST ) &gt; =1.5xULN ; alkaline phosphatase bilirubin &gt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment ) Clinically significant unstable uncontrolled acute chronic disease ( e.g. , cardiovascular include uncompensated congestive cardiac failure New York Heart Association [ NYHA ] III IV , myocardial infarction within 12 month , unstable angina pectoris , uncontrolled hypertension , uncontrolled hypercholesterolemia ) pulmonary , hematologic , gastrointestinal ( include Crohn 's Disease ulcerative colitis ) , hepatic , renal , neurological , psychiatric , malignancy , endocrinological infectious disease , , opinion investigator , could confound result study put subject undue risk A history malignant neoplasm within last 10 year breast cancer within last 20 year , except nonmelanoma skin cancer excise cured carcinoma situ uterine cervix Kidney disease : Current history renal disease , estimate creatinine clearance &lt; 60 milliliter ( mL ) /minute ( min ) /1.73 m2 ( MDRD formula ) serum creatinine &gt; 1.5xULN within 4 week Day 1 Hereditary acquire immunodeficiency disorder , include immunoglobulin deficiency History infect joint prosthesis time , prosthesis still situ . History leg ulcer , catheter , chronic sinusitis recurrent chest urinary tract infection Active infection , history recurrent infection ( exclude recurrent fungal infection nail bed ) , require management acute chronic infection , follow : Currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) OR Hospitalization treatment infection within 26 week Day 1 OR Use parenteral ( Intravenous ( IV ) Intramuscular ( IM ) antimicrobial ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 26 week Day 1 oral antimicrobial within 2 week Day 1 A vaccination ( live attenuate ) within 30 day Day 1 Bacillus CalmetteGuérin ( BCG ) vaccination within 1 year Day 1 , live vaccination plan course study ( include followup period ) . Any surgical procedure , include bone joint surgery/synovectomy within 12 week prior Day 1 plan surgery within duration study ( include followup period ) Use prohibit medication Prior AND throughout study : Any conventional DMARDs MTX ( include sulfasalazine , bucillamine , iguratimod , tacrolimus ) withdrawn least 2 week prior Day 1 . Subjects may require long discontinue azathioprine leflunomide prior Day 1 : Azathioprine must discontinue &gt; =4 week prior randomization ; Leflunomide must discontinue &gt; =12 week prior Day 1 ( &gt; =14 day 11 day standard cholestyramine activate charcoal washout ) . For subject , write informed consent study must obtain prior begin screen period . However , screen assessment , consent , must occur within 4 week prior Day 1 . Any biologic agent ( Tumor necrosis factor ( TNF ) inhibitor [ include adalimumab , etanercept , infliximab , certolizumab pegol , golimumab ] nonTNF inhibitor [ include abatacept , rituximab , tocilizumab , belimumab ] ) . Any Janus kinase ( JAK ) inhibitor ( tofacitinib ) . Any antirheumatic investigational compound . Any alkylating agent ( cyclophosphamide ) . Plasmapheresis intravenous immunoglobulin ( IVIG ) within 26 week Day 1 . Corticosteroids : Any Intramascular ( IM ) , Intravenous ( IV ) Intraarterial ( IA ) corticosteroid within 8 week Day 1 . Oral corticosteroid : Any treatment &gt; 10 mg/day dose oral prednisolone ( equivalent ) within 4 week Day 1 . New oral corticosteroid change corticosteroid dose within 4 week prior Day 1 . ( New topical steroid immunosuppressive agent ( e.g. , eye drop , cream ) permit ) Nonsteroidal antiinflammatory drug ( NSAIDs ) : New change dose NSAID within 2 week Day 1 Any nonantirheumatic investigational treatment must discontinue least 4 week 5 halflives , whichever longer , prior Day 1 Have current drug alcohol abuse dependence , history drug alcohol abuse dependence within year prior Day 1 History sensitivity study treatment , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation Abnormal chest Xray within 12 week Day 1 ( locally read report radiologist ) judge investigator clinicallysignificant Any Grade 3 4 hematology clinical chemistry laboratory abnormality , within 4 week Day 1 Hemoglobin ≤9 g/dL ; white blood cell count ≤3.0 x 109/L ; platelet count ≤100 x 109/L ; absolute neutrophil count ≤1.5 x 109/L ; lymphocyte count ≤0.5 x 109/L within 4 week Day 1 Serologic evidence current/previous Hepatitis B virus ( HBV ) infection base result test Hepatitis B surface antigen ( HBsAg ) antiHepatitis B core ( antiHBc ) antibody follow within 4 week Day 1 Subjects positive HBsAg and/or positive antiHBc antibody ( regardless antiHBs antibody status ) exclude Subjects positive antiHBs antibody HBVDNA ( &gt; =2.1 log copies/mL ) exclude . Hepatitis C : Positive test Hepatitis C virus ( HCV ) antibody confirm subsequent blood sample ribonucleic acid polymerize chain reaction ( RNAPCR ) assay within 4 week Day 1 . Subjects positive Hepatitis C antibody negative Hepatitis C RNAPCR assay perform subsequent sample eligible participate . Subjects positive Hepatitis C antibody positive result HCV Hepatitis C RNAPCR assay perform subsequent sample eligible participate Positive serology human immunodeficiency virus ( HIV ) 1 2 ( within 4 week Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK3196165</keyword>
	<keyword>Active Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Electrocardiogram</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese Subjects</keyword>
</DOC>